Practice support

The Berinert Expert Network

The Berinert Expert Network (B.E.N.™) is available toll-free 24 hours a day, 7 days a week, to help you and your staff:

Call B.E.N.™ toll-free 24/7 at 1-877-BEN-4HAE (1-877-236-4423)

To enroll with B.E.N.™, simply call the number above or download this form. Enrollment is open to all patients.

Get access to Berinert

  • Easy access to specialty pharmacies that carry Berinert
  • Help your local hospital network gain access to Berinert

Navigate insurance issues and questions

  • Complete a benefits investigation for your patients, facilitate authorization requests, assist with coding, and answer reimbursement questions
  • Address issues that may arise with your patients’ insurance companies, such as prior authorization, coverage appeals, and letters of medical necessity

Offer valuable CSL Behring programs to your patients who need them

Assurance program

Access Berinert if your patients experience a lapse in third-party private health insurance

Assistance program

Access Berinert for your qualified patients who are uninsured or underinsured or cannot afford their prescribed therapy

Call B.E.N.™ toll-free 24/7 at 1-877-BEN-4HAE (1-877-236-4423)

Obtaining Berinert

You can obtain Berinert at one of CSL Behring’s preferred hospital distributors:

  • ASD
  • Biocare
  • BDI Pharma
  • Cardinal
  • FFF
  • McKesson

You can also find Berinert at the following home healthcare companies/specialty pharmacies:

  • Accredo
  • Biofusion
  • BioRx
  • BioScrip
  • Caremark
  • Coram
  • Crescent
  • CuraScript
  • Walgreens

If you need contact information for these organizations, please call B.E.N.™ toll-free 24/7 at 1-877-BEN-4HAE (1-877-236-4423).

Additional Resources

US Hereditary Angioedema Association

The US Hereditary Angioedema Association provides a wide range of services, including clinical trial placement, physician referrals, education, and individualized patient case management.

AllAboutHAE.com

AllAboutHAE.com offers information about hereditary angioedema, the ability to submit questions to an HAE expert, and current information on treatments and clinical trials.

American Academy of Allergy Asthma & Immunology (AAAAI)

The AAAAI is devoted to advancing the knowledge and practice of allergy, asthma, and immunology for optimal patient care.

American College of Allergy, Asthma & Immunology (ACAAI)

The ACAAI is dedicated to improving the quality of patient care in allergy and immunology through research, advocacy, and professional and public education.

Important Safety Information

Berinert®, C1 Esterase Inhibitor (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients. The safety and efficacy of Berinert for prophylactic therapy have not been established.

Berinert is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of Berinert and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Thrombotic events have been reported in patients receiving C1 esterase inhibitor products, including Berinert, at the recommended dose as well as when used off-label or at higher-than-labeled doses. Closely monitor patients with risk factors for thrombotic events.

Patients able to recognize signs and symptoms of HAE attack and comprehend necessary training can self-administer Berinert. Patients should not attempt to self-administer unless they have been trained and determined to be capable by healthcare provider. Advise patients to immediately seek medical attention following self-administration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of Berinert.

Berinert is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received Berinert in clinical studies was an increase in the severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

Berinert has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. The safety and efficacy of Berinert have not been established in children (ages 0 through 12) or in the geriatric population. In clinical trials, the half-life of Berinert was shorter and clearance was faster in children than in adults; the clinical implication is not known.

Please see full Prescribing Information.